South Florida names John P. Diaz, M.D. ...

Dr. John Diaz, MD

Claim this profile

Miami Cancer Institute at Baptist Health, Inc.

Studies Ovarian Cancer
Studies Fallopian Tube Cancer
9 reported clinical trials
19 drugs studied

Area of expertise

1Ovarian Cancer
John Diaz, MD has run 6 trials for Ovarian Cancer. Some of their research focus areas include:
Stage IV
Stage III
2Fallopian Tube Cancer
John Diaz, MD has run 3 trials for Fallopian Tube Cancer. Some of their research focus areas include:
Stage IV
Stage III

Affiliated Hospitals

Image of trial facility.
Miami Cancer Institute
Image of trial facility.
South Miami Hospital

Clinical Trials John Diaz, MD is currently running

Image of trial facility.

Robotic vs Open Hysterectomy

for Cervical Cancer

This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Recruiting1 award N/A8 criteria
Image of trial facility.

Heated Chemotherapy + Niraparib

for Ovarian Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 3-4 cycles). Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at the time of iCRS (iCRS must achieve no gross residual disease or no disease \>1.0 cm in largest diameter) to receive HIPEC or no HIPEC. Patients randomized to HIPEC (Arm A) will receive a single dose of cisplatin (100mg/m2 IP over 90 minutes at 42 C) as HIPEC. After postoperative recovery patients will receive standard post-operative platinum-based combination chemotherapy. Patients randomized to surgery only (Arm B) will receive postoperative standard chemotherapy after recovery from surgery. Both groups will receive an additional 2-3 cycles of platinum-based combination chemotherapy per institutional standard (Paclitaxel 175 mg/m2 IV over 3 hours and Carboplatin AUC 6 IV on Day 1 every 21 days for 2-3 cycles) for a maximum total of 6 cycles of chemotherapy (neoadjuvant plus post-operative cycles) followed by niraparib individualized dosing until progression or 36 months (if no evidence of disease).
Recruiting2 awards Phase 3

More about John Diaz, MD

Clinical Trial Related6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments John Diaz, MD has experience with
  • Niraparib
  • Olaparib
  • Pembrolizumab
  • Defactinib
  • Avutometinib (VS-6766)
  • STRO-002

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does John Diaz, MD specialize in?
Is John Diaz, MD currently recruiting for clinical trials?
Are there any treatments that John Diaz, MD has studied deeply?
What is the best way to schedule an appointment with John Diaz, MD?
What is the office address of John Diaz, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security